Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could help when blood pressure pills Aren't enough

NCT ID NCT05103332

Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called zilebesiran in 663 adults whose high blood pressure was not well controlled by their current pills. Participants received either zilebesiran or a placebo added to their usual treatment. The goal was to see if the new drug could lower blood pressure more effectively and safely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

663 people

The number who actually took part.

Started

Nov 2021

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Office SBP at Screening as follows: 1. ≥155 mmHg and ≤180 mmHg for patients with untreated hypertension 2. ≥145 mmHg and ≤180 mmHg for patients on antihypertensive medications * 24-hour mean SBP ≥130 mmHg and ≤160 mmHg by ABPM after at least 4 weeks of run-in Exclusion Criteria: * Secondary hypertension, orthostatic hypotension * Elevated potassium \<lower limit of normal (LLN) range or \>5 milliequivalents per liter (mEq/L) * Estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m\^2 * Received an investigational agent within the last 30 days * Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, or laboratory evidence of diabetes during screening without known diagnosis of diabetes * History of any cardiovascular event within 6 months prior to randomization * History of intolerance to SC injection(s)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Clinical Trial Site

    Mesa, Arizona, 85213, United States

  • Clinical Trial Site

    Tempe, Arizona, 85281, United States

  • Clinical Trial Site

    Tempe, Arizona, 85282, United States

  • Clinical Trial Site

    Bell Gardens, California, 90201, United States

  • Clinical Trial Site

    Canoga Park, California, 91304, United States

  • Clinical Trial Site

    Carlsbad, California, 92008, United States

  • Clinical Trial Site

    Encinitas, California, 92024, United States

  • Clinical Trial Site

    Garden Grove, California, 92844, United States

  • Clinical Trial Site

    Hollywood, California, 91606, United States

  • Clinical Trial Site

    Huntington Beach, California, 92647, United States

  • Clinical Trial Site

    Irvine, California, 92614, United States

  • Clinical Trial Site

    Long Beach, California, 90805, United States

  • Clinical Trial Site

    Los Angeles, California, 90057, United States

  • Clinical Trial Site

    Mission Hills, California, 91345, United States

  • Clinical Trial Site

    Oceanside, California, 92056, United States

  • Clinical Trial Site

    Panorama City, California, 91402, United States

  • Clinical Trial Site

    San Diego, California, 92103, United States

  • Clinical Trial Site

    Santa Clarita, California, 91355, United States

  • Clinical Trial Site

    South Gate, California, 90280, United States

  • Clinical Trial Site

    Tustin, California, 92780, United States

  • Clinical Trial Site

    Upland, California, 91786, United States

  • Clinical Trial Site

    Washington D.C., District of Columbia, 20011, United States

  • Clinical Trial Site

    Clearwater, Florida, 33756, United States

  • Clinical Trial Site

    Coconut Creek, Florida, 33073, United States

  • Clinical Trial Site

    Coral Gables, Florida, 33134, United States

  • Clinical Trial Site

    Hollywood, Florida, 33021, United States

  • Clinical Trial Site

    Hollywood, Florida, 33024, United States

  • Clinical Trial Site

    Inverness, Florida, 34452, United States

  • Clinical Trial Site

    Jacksonville, Florida, 32256, United States

  • Clinical Trial Site

    Miami, Florida, 33032, United States

  • Clinical Trial Site

    Miami, Florida, 33125, United States

  • Clinical Trial Site

    Miami, Florida, 33135, United States

  • Clinical Trial Site

    Miami, Florida, 33144, United States

  • Clinical Trial Site

    Miami, Florida, 33176, United States

  • Clinical Trial Site

    Naples, Florida, 34105, United States

  • Clinical Trial Site

    Orlando, Florida, 32162, United States

  • Clinical Trial Site

    Orlando, Florida, 32801, United States

  • Clinical Trial Site

    Pembroke Pines, Florida, 33027, United States

  • Clinical Trial Site

    Tampa, Florida, 33603, United States

  • Clinical Trial Site

    Winter Haven, Florida, 33880, United States

  • Clinical Trial Site

    Winter Park, Florida, 32789, United States

  • Clinical Trial Site

    Acworth, Georgia, 30101, United States

  • Clinical Trial Site

    Canton, Georgia, 30114, United States

  • Clinical Trial Site

    Columbus, Georgia, 31904, United States

  • Clinical Trial Site

    Savannah, Georgia, 31406, United States

  • Clinical Trial Site

    Louisville, Kentucky, 40202, United States

  • Clinical Trial Site

    New Orleans, Louisiana, 70769, United States

  • Clinical Trial Site

    Southgate, Michigan, 48195, United States

  • Clinical Trial Site

    Jackson, Mississippi, 39209, United States

  • Clinical Trial Site

    Hazelwood, Missouri, 63042, United States

  • Clinical Trial Site

    Jefferson City, Missouri, 65109, United States

  • Clinical Trial Site

    New York, New York, 10036, United States

  • Clinical Trial Site

    Greensboro, North Carolina, 27403, United States

  • Clinical Trial Site

    Greensboro, North Carolina, 27410, United States

  • Clinical Trial Site

    Monroe, North Carolina, 28112, United States

  • Clinical Trial Site

    Norman, Oklahoma, 73072, United States

  • Clinical Trial Site

    Little River, South Carolina, 29566, United States

  • Clinical Trial Site

    Memphis, Tennessee, 38119, United States

  • Clinical Trial Site

    Amarillo, Texas, 79109, United States

  • Clinical Trial Site

    Coppell, Texas, 75019, United States

  • Clinical Trial Site

    Dallas, Texas, 75251, United States

  • Clinical Trial Site

    Houston, Texas, 77074, United States

  • Clinical Trial Site

    Houston, Texas, 77081, United States

  • Clinical Trial Site

    Lake Jackson, Texas, 77566, United States

  • Clinical Trial Site

    Plano, Texas, 75024, United States

  • Clinical Trial Site

    Sherman, Texas, 75092, United States

  • Clinical Trial Site

    Splendora, Texas, 77372, United States

  • Clinical Trial Site

    Stephenville, Texas, 76401, United States

  • Clinical Trial Site

    Tomball, Texas, 77375, United States

  • Clinical Trial Site

    Waco, Texas, 76708, United States

  • Clinical Trial Site

    Burke, Virginia, 22015, United States

  • Clinical Trial Site

    Kenosha, Wisconsin, 53142, United States

  • Clinical Trial Site

    Brampton, Ontario, Canada

  • Clinical Trial Site

    Concord, Ontario, Canada

  • Clinical Trial Site

    London, Ontario, N5W 6A2, Canada

  • Clinical Trial Site

    Toronto, Ontario, Canada

  • Clinical Trial Site

    Winnipeg, Ontario, Canada

  • Clinical Trial Site

    Chicoutimi, Quebec, Canada

  • Clinical Trial Site

    Lévis, Quebec, Canada

  • Clinical Trial Site

    Pointe-Claire, Quebec, Canada

  • Clinical Trial Site

    Québec, Quebec, Canada

  • Clinical Trial Site

    Sherbrooke, Quebec, Canada

  • Clinical Trial Site

    Trois-Rivières, Quebec, Canada

  • Clinical Trial Site

    Québec, Canada

  • Clinical Trial Site

    Tartu, Estonia

  • Clinical Trial Site

    Frankfurt, Germany

  • Clinical Trial Site

    Riga, Latvia

  • Clinical Trial Site

    Kaunas, Lithuania

  • Clinical Trial Site

    Vilnius, Lithuania

  • Clinical Trial Site

    Częstochowa, Poland

  • Clinical Trial Site

    Gdansk, Poland

  • Clinical Trial Site

    Katowice, Poland

  • Clinical Trial Site

    Staszów, Poland

  • Clinical Trial Site

    Warsaw, Poland

  • Clinical Trial Site

    Wroclaw, Poland

  • Clinical Trial Site

    Bellshill, Lanarkshire, ML4 3NJ, United Kingdom

  • Clinical Trial Site

    Carshalton, United Kingdom

  • Clinical Trial Site

    Edinburgh, United Kingdom

  • Clinical Trial Site

    Fowey, United Kingdom

  • Clinical Trial Site

    Glasgow, United Kingdom

  • Clinical Trial Site

    Lancashire Preston, United Kingdom

  • Clinical Trial Site

    Liskeard, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    Manchester, United Kingdom

  • Clinical Trial Site

    Newquay, United Kingdom

  • Clinical Trial Site

    Plymouth, United Kingdom

  • Clinical Trial Site

    Sheffield, United Kingdom

  • Clinical Trial Site

    Torpoint, United Kingdom

  • Clinical Trial site

    Winston-Salem, North Carolina, 27157, United States

  • Clinical Trials Site

    Beverly Hills, California, 90211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.